$625 million-deal includes entire portfolio of products, candidates and three manufacturing facilities.
Baxter International provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; surgery products and anesthetics; and pharmacy automation, software and services. With the completion of its $625-million acquisition of Claris Injectables, Baxter increases its presence in the generic injectables market.
Claris Injectables was a wholly-owned subsidiary of Claris Lifesciences. The company formulates, fills and finishes a broad portfolio of essential generic medicines with complementary strengths in anesthesia and analgesics, critical care and renal medicines and anti-infectives—including antibiotics, antiprotozoals, antifungals and antivirals—in a variety of presentations including bags, vials and ampoules.
As part of the deal, Baxter receives the entire Claris Injectables product portfolio and pipeline, along with three manufacturing plants. Baxter has already indicated that it will be investing in these facilities to increase both capacity and technical capabilities, such as the addition of aseptic manufacturing and lyophilization systems, the introduction of new technology platforms (cytotoxics, aseptic development and complex formulations) and the expansion of Claris’ R&D footprint for greater candidate development.
Baxter is combining Claris Injectables’ capabilities, technologies and expertise with its manufacturing experience and presence in the hospital channel, with Claris Injectables continuing to manufacture and supply its products to customers as usual. It expects the acquisition will drive growth of its portfolio in both the near- and long-terms. For example, Baxter will add 50 products in 2017, nearly 20 new products in 2018 and 2019 and 10-15 yearly, starting in 2020.
“This acquisition reinforces our commitment to establishing Baxter as a global leader in generic injectable medicines,” said Baxter’s Chairman and CEO José Almeida, “The combination of Baxter and Claris Injectables will allow us to increase access to lower-cost generic injectables and strengthen our ability to meet the needs of healthcare providers and patients around the world,” he stated.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.